# US 12,005,135 B2 · Barrier guard technology

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,005,135 B2
- Document ID: US12005135B2
- Status: Granted
- Kind: B2
- Application number: 17/804,369
- Filed: 2022-05-27
- Published: 2022-12-08
- Granted: 2024-06-11
- Earliest claimed: 2021-05-28
- Assignees: Mary Kay Inc.
- Applicants: Mary Kay Inc.
- Inventors: Geetha Kalahasti; David Gan
- Web page: https://patentgrep.com/patent/US12005135B2

## CPC

- A61K 8/63: Steroids; Derivatives thereof
- A61Q 19/00: Preparations for care of the skin
- A61K 8/442: {substituted by amido group(s)}
- A61K 8/60: Sugars; Derivatives thereof
- A61K 8/68: Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
- A61K 8/922: {of vegetable origin}
- A61Q 19/007: {Preparations for dry skin}
- A61Q 19/08: Anti-ageing preparations
- A61K 2800/72: Hypo-allergenic
- A61K 2800/78: Enzyme modulators, e.g. Enzyme agonists
- A61K 2800/782: Enzyme inhibitors; Enzyme antagonists
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The present invention relates generally to methods and compositions useful for improving skin barrier function and reducing skin redness. The compositions comprise cholesterol, ceramide II, and shea butter or cholesterol, ceramide II, shea butter, saccharide isomerate, hydroxyphenyl propamidobenzoic acid, and Phoenix dactylifera (date palm) seed extract.

## Claims

### Claim 1

A method of reducing skin redness, comprising applying to reddened skin a topical composition comprising:
cholesterol;
ceramide II;
shea butter; and
one or more of:
a plankton extract
an Phoenix dactylifera seed extract
an alpha-adrenergic receptor agonists; and/or
wherein the cholesterol, ceramide II, and shea butter are provided in the composition at a wt. ratio of 3:1:1, and
wherein the redness of the skin is decreased.

### Claim 2 (depends on 1)

The method of claim 1, wherein the plankton extract comprises saccharide isomerate.

### Claim 3 (depends on 1)

The method of claim 1, wherein the composition further comprises hydroxyphenyl propamidobenzoic acid.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition further comprises Natural Moisturizing Factor.

### Claim 5 (depends on 1)

The method of claim 1, wherein the composition further comprises one or more nitric oxide synthase inhibitors.

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition further comprises water.

### Claim 7 (depends on 6)

The method of claim 6, wherein the composition comprises 25% to 98% by weight of water.

### Claim 8 (depends on 1)

The method of claim 1, wherein the composition further comprises saccharide isomerate and hydroxyphenyl propamidobenzoic acid.

### Claim 9 (depends on 1)

The method of claim 1, wherein the Phoenix dactylifera seed extract is a water soluble extract.

### Claim 10 (depends on 1)

The method of claim 1, wherein the composition is formulated as an emulsion.

### Claim 11 (depends on 10)

The method of claim 10, wherein the composition is formulated as a cream.

### Claim 12

A method of treating skin, comprising applying to skin a topical composition comprising:
cholesterol;
ceramide II;
shea butter; and
one or more of:
a plankton extract
an Phoenix dactylifera seed extract
an alpha-adrenergic receptor agonists; and/or
wherein the cholesterol, ceramide II, and shea butter are provided in the composition at a wt. ratio of 3:1:1, and
wherein expression of pro-inflammatory cytokines is reduced, expression of pro-inflammatory chemokines is reduced, expression of nitric oxide synthase is reduced, expression of one or more tight junction-associated proteins is increased, expression of occludin 1 is increased, and/or expression of filaggrin is increased.

### Claim 13 (depends on 12)

The method of claim 12, wherein the composition further comprises saccharide isomerate and hydroxyphenyl propamidobenzoic acid.

### Claim 14 (depends on 12)

The method of claim 12, wherein the composition further comprises Natural Moisturizing Factor.

### Claim 15 (depends on 12)

The method of claim 12, wherein the composition further comprises a nitric oxide synthase inhibitor and/or an alpha-adrenergic receptor agonist.